In Vitro Evaluation of Faropenem Activity Against Anaerobic Bacteria

References

• Viaene E, Chanteux H, Servais H, Mingeot-Leclercq MP, Tulkens PM. Comparative stability studies of antipseudomonal I3-lactams for potential administration through portable elastomeric pumps (home-therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother 2002; 46: 2327-2332.
   Google Scholar
• Rylander M, Nord CE, Norrby SR. Comparative in vitro activity of the new oral penem ALP-201 against aerobic and anaerobic bacteria. Eur J Clin Microbiol Infect Dis 1989; 8: 919–924.
   PubMed Web of Science ®Google Scholar
• Woodcock JM, Andrews JM, Brenwald NP, Ashby JP, Wise R. The in-vitro activity of faropenem, a novel penem. J Antimicrob Chemother 1997; 39: 35–43.
   PubMed Web of Science ®Google Scholar
• Cormican MG, Jones RN. Evaluation of the in-vitro activity of faropenem (SY 5555 or SUN 5555) against respi-ratory tract pathogens and I3-lactamase producing bacteria. J Antimicrob Chemother 1995; 35: 535–539.
   PubMed Web of Science ®Google Scholar
• Mortensen JE, Egleton JH. Comparative activity of faropenem against aerobic bacteria isolated from pediatric patients. Diagn Microbiol Infect Dis 1995; 22: 301–306.
   PubMed Web of Science ®Google Scholar
• Black JA, Smith Moland E, Chartrand SA, Thompson KS. Activity of faropenem against resistant isolates of Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2001; 41: 89–92.
   PubMed Web of Science ®Google Scholar
• Walsh F, Amyes AKB, Amyes SGB. The in vitro effects of faropenem on lower respiratory tract pathogens isolated in the United Kindom. Int J Antimicrob Agents 2003; 21: 581–584.
   PubMed Web of Science ®Google Scholar
• Jones ME, Blosser-Middleton RS, Critchley IA, Karlowsky JA, Thornsberry C, Sahm DF. Activity of faropen-em a new furanem against European respiratory pathogens collected during 2000-2001: a comparison with other I3-lac-tam agents. J Antimicrob Chemother 2003; 51: 196–199.
   PubMed Web of Science ®Google Scholar
• Nord CE, Lindmark A, Persson I. Susceptibility of anaer-obic bacteria to ALP 201. Antimicrob Agents Chemother 1989; 33: 2137-2139.
   Google Scholar
• Goldstein EJC, Citron DM, Vreni Merriam C., Warren YA, Tyrrell KL, Fernandez HT. Comparative in vitro activity of faropenem and 11 other antimicrobial agents against 405 aerobic and anaerobic pathogens isolated from skin and soft tissue infections from animal and human bites. J Antimicrob Chemother 2002; 50: 411–420.
   PubMed Web of Science ®Google Scholar
• Wexler HM, Molitoris D, St. John S, Vu A, Read E, Finegold SM. In vitro activities of faropenem against 579 strains of anaerobic bacteria. Antimicrob Agents Chemother 2002; 46: 3669-3675.
   Google Scholar
• Milazzo I, Blandino G, Caccamo F, Musumeci R, Nicoletti G, Speciale A. Faropenem, a new oral penem: antibacterial activity against selected anaerobic and fastidious periodontal isolates. J Antimicrob Chemother 2003; 51: 721–725.
   PubMed Web of Science ®Google Scholar
• Amyes SG. Resistance to beta-lactams-the permuta-tions. J Chemother 2003; 15 (6): 525–35.
   PubMed Web of Science ®Google Scholar
• MacGowan A, Bowker K. In vitro studies on the impact of human serum on the antibacterial effect of faropenem. J Chemother 2004; 16 (1): 23–9.
   PubMed Web of Science ®Google Scholar
• Jousimies-Somer H, Summanen P, Citron DM, Jo Baron E, Wexler HM, Finegold SM. In: Stuart Hoffman Ed. Wadsworth-KTL Anaerobic Bacteriology Manual, 6th ed. Belmont, CA: Star Publishing Company. 2002: 43-287.
   Google Scholar
• Brazier JS, Citron DM, Goldstein EJC. A selective medium for Fusobacterium spp. J Appl Bacteriol 1991; 71: 343–346.
   PubMedGoogle Scholar
• National Committee for Clinical Laboratory Standards. Approved standard M7-A3. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 3rd ed. National Committee for Clinical Laboratory Standards, Villanova Pa, 1993.
   Google Scholar
• Appelbaum PC, Spangler SK, Jacobs MR. Evaluation of two methods for reading testing for I3-lactamase production in Bacteroides and Fusobacterium. Eur J Clin Infect Dis 1990; 9: 47–50.
   PubMed Web of Science ®Google Scholar
• National Committee for Clinical Laboratory Standards. Reference dilution procedure for antimicrobial testing of anaerobic bacteria. Approved standard, NCCLS publication M-11T. National Committee for Clinical Laboratory Standards, Villanova Pa, 1979.
   Google Scholar
• National Committee for Clinical Laboratory Standards. Methods for antimicrobial testing of anaerobic bacteria-second edition. Approved standard, NCCLS publication M11-A2 National Committee for Clinical Laboratory Standards, Villanova Pa, 1990.
   Google Scholar
• Ericsson HM, Sherris JC. Antibiotic sensitivity testing: report of an international collaborative study, Acta Pathol Microbiol Scand 1971; Sect. B (Suppl) 127: 1-90.
   Google Scholar
• Boswell FJ, Andrews JM, Wise R. Pharmacodynamic properties of faropenem demonstrated by studies of time-kill kinetics and postantibiotic effect. J Antimicrob Chemother 1997; 39: 415–418.
   PubMed Web of Science ®Google Scholar
• Aldridge KE, Gelfand M, Reller LB et al. A five-year multicenter study of the susceptibility of the Bacteroides frag-ilis group isolates to cephalosporins, cephamycins, penicillins, clindamycin, metronidazole in the United States. Diagn Microbiol Infect Dis 1994; 18: 235–241.
   PubMed Web of Science ®Google Scholar
• Behra-Miellet J, Calvet L, Dubreuil L. Activity of linezolid against anaerobic bacteria. Int J Antimicrob Agents; 2003; 22: 28–34.
   PubMed Web of Science ®Google Scholar
• Behra-Miellet J, Calvet L, Mory F et al. Antibiotic resis-tance among anaerobic Gram-negative bacilli : lessons from a French multicentric survey. Anaerobe 2003; 9: 105–111.
   Google Scholar
• Rogers MB, Parker AC, Smith CJ. Cloning and charac-terization of the endogenous cephalosporinase gene, cepA, from Bacteroides fragilis reveals a new subgroup of Ambler class A beta-lactamase. Antimicrob Agents Chemother 1993; 37: 2391–2400.
   PubMed Web of Science ®Google Scholar
• Rogers MB, Bennett TK, Payne CM, Smith CJ. Insertional activation of cepA leads to high-level beta-lacta-mase expression in Bacteroides fragilis clinical isolates. J. Bacteriol 1994; 176: 4376–4384.
   PubMed Web of Science ®Google Scholar
• Odou MF, Singer E, Romond MB, Dubreuil L. Isolation and characterization of a porin-like protein of 45 kilodaltons from Bacteroides fragilis. FEMS Microbiol Lett 1998; 166: 347–354.
   PubMed Web of Science ®Google Scholar
• Behra-Miellet J, Calvet L, Dubreuil L. A Bacteroides thetaiotaomicron porin that could take part in resistance to 13-lactams. Int J Antimicrob Agents 2004; 24: 135–143.
   PubMed Web of Science ®Google Scholar
• Wexler HM. In vitro activity of ertapenem: review of recent studies. J Antimicrob Chemother 2004; 53 Suppl S2: 11–21.
   Google Scholar
• Rasmussen BA, Kovacs E. Cloning and identification of a two-component signal-tranducing regulatory system from Bacteroides fragilis. Mol Microbiol 1993; 7: 765–776.
   PubMed Web of Science ®Google Scholar
• Podglagen I, Breuil J, Collatz E. Insertion of a novel DNA sequence, IS1186, upstream of the silent carbapene-mase gene cfia, promotes expression of carbapenem resis-tance in clinical isolates of Bacteroides fragilis. Mol Microbiol 1994; 12: 105–114.
   PubMed Web of Science ®Google Scholar
• Podglagen I, Breuil J, Rohaut A, Monsempes C, Collatz E. Multiple mobile promoter regions for the rare carbapenem resistance gene of Bacteroides fragilis. J Bacteriol 2001; 183: 3531–3535.
   PubMed Web of Science ®Google Scholar
• Piddock II, Wise R. Cefoxitin resistance in Bacteroides species: evidence indicating two mechanisms causing decreased susceptibility. J Antimicrob Chemother 1987; 19: 161–170.
   PubMed Web of Science ®Google Scholar
• Podlagen I, Breuil J, Bordon F, Gutmann L, Collatz E. A silent carbapenemase gene in strains of Bacteroides fragilis can be expressed after a one-step mutation. FEMS Microbiol Lett 1992; 91: 21–30.
   Web of Science ®Google Scholar
• Wexler H. Outer-membrane pore-forming proteins in Gram-negative anaerobic bacteria. Clin Infect Dis 2002; 35 (Suppl 1): 65–71.
   PubMed Web of Science ®Google Scholar
• Grollier G, Mory F, Quentin F et al. Survey of anaero-bic susceptibility patterns: a French multicentric study. Path Biol 1994; 42: 498–504.
   Google Scholar
• Bland S, Sedallian A, Grollier G, Mory F, Houcke I, Dubreuil. In vitro activity of three carbapenems biapenem, imipenem and meropenem and some other antibiotics against anaerobic bacteria. Path Biol 1995; 43: 289–293.
   Google Scholar